Megumi Saito
Research Subjects
Megumi Saito has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Kazuhiro Okumura
Division of Experimental Animal Research, Cancer Genome Center, Chiba Cancer Center Research Institute, Chiba, Japan
4 shared publications - Yuichi Wakabayashi
Division of Experimental Animal Research, Cancer Genome Center, Chiba Cancer Center Research Institute, Chiba, Japan
4 shared publications - Eriko Isogai
Division of Experimental Animal Research, Cancer Genome Center, Chiba Cancer Center Research Institute, Chiba, Japan
3 shared publications - Kimi Araki
Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan
2 shared publications - Yurika Tokunaga
Division of Experimental Animal Research, Cancer Genome Center, Chiba Cancer Center Research Institute, Chiba, Japan
2 shared publications - Akane Sada
Laboratory of Fundamental Oncology, National Cancer Center Research Institute
1 shared publication
Latest Publications
- 5 February 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (8) , 1890-1893.e5
Deletion of Pak1 in CD11c-Positive Cells Confers Resistance to Mouse Skin Carcinogenesis
- 5 February 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (8) , 1890-1893.e5
Deletion of Pak1 in CD11c-Positive Cells Confers Resistance to Mouse Skin Carcinogenesis
- 1 April 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (4) , 1040-1049.e8
PHLDA3 Is an Important Downstream Mediator of p53 in Squamous Cell Carcinogenesis
- 1 April 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (4) , 1040-1049.e8
PHLDA3 Is an Important Downstream Mediator of p53 in Squamous Cell Carcinogenesis
- 1 March 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (9) , 2323-2333.e12
Functional Polymorphism in Pak1–3′ Untranslated Region Alters Skin Tumor Susceptibility by Alternative Polyadenylation
- 1 March 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (9) , 2323-2333.e12
Functional Polymorphism in Pak1–3′ Untranslated Region Alters Skin Tumor Susceptibility by Alternative Polyadenylation
- Open Access
- 14 June 2020
- Published by Wiley in Cancer Science
- Vol. 111 (8) , 2850-2860
CENP‐50 is required for papilloma development in the two‐stage skin carcinogenesis model
CENP‐50/U is a component of the CENP‐O complex (CENP‐O/P/Q/R/U) and localizes to the centromere throughout the cell cycle. Aberrant expression of CENP‐50/U has been reported in many types of cancers. However, as Cenp‐50/U‐deficient mice die during early embryogenesis, its functions remain poorly understood in vivo. To investigate the role of Cenp‐50/U in skin carcinogenesis, we generated Cenp‐50/U conditional knockout (K14CreER‐Cenp‐50/U fl/fl) mice and subjected them to the 7,12‐dimethylbenz(a)anthracene (DMBA)/terephthalic acid (TPA) chemical carcinogenesis protocol. As a result, early‐stage papillomas decreased in Cenp‐50/U‐deficient mice. In contrast, Cenp‐50/U‐deficient mice demonstrated almost the same carcinoma incidence as control mice. Furthermore, mRNA expression analysis using DMBA/TPA‐induced papillomas and carcinomas revealed that Cenp‐50/U expression levels in papillomas were significantly higher than in carcinomas. These results suggest that Cenp‐50/U functions mainly in early papilloma development and it has little effect on malignant conversion.
- 14 June 2020
- Published by Wiley in Cancer Science
- Vol. 111 (8) , 2850-2860
Open AccessCENP‐50 is required for papilloma development in the two‐stage skin carcinogenesis model
CENP‐50/U is a component of the CENP‐O complex (CENP‐O/P/Q/R/U) and localizes to the centromere throughout the cell cycle. Aberrant expression of CENP‐50/U has been reported in many types of cancers. However, as Cenp‐50/U‐deficient mice die during early embryogenesis, its functions remain poorly understood in vivo. To investigate the role of Cenp‐50/U in skin carcinogenesis, we generated Cenp‐50/U conditional knockout (K14CreER‐Cenp‐50/U fl/fl) mice and subjected them to the 7,12‐dimethylbenz(a)anthracene (DMBA)/terephthalic acid (TPA) chemical carcinogenesis protocol. As a result, early‐stage papillomas decreased in Cenp‐50/U‐deficient mice. In contrast, Cenp‐50/U‐deficient mice demonstrated almost the same carcinoma incidence as control mice. Furthermore, mRNA expression analysis using DMBA/TPA‐induced papillomas and carcinomas revealed that Cenp‐50/U expression levels in papillomas were significantly higher than in carcinomas. These results suggest that Cenp‐50/U functions mainly in early papilloma development and it has little effect on malignant conversion.